After signing up, you'll start to receive regular news updates from us.
Fluxion Biosciences Launches BioFlux System for Automated Biofilm Analysis
Complete the form below to unlock access to ALL audio articles.
Fluxion Biosciences have announced the commercial launch of its BioFlux platform, which provides automated biofilm analysis for disease research and drug discovery applications.
Biofilms are bacterial or fungal layers that form in the body and are extremely resistant to antibiotics. Biofilms are implicated in a number of diseases including cystic fibrosis and pneumonia.
The BioFlux™ system has been designed to meet the demands of scientists in disease research and drug discovery in the pharma, biotech, and academic communities.
The system automates and combines a number of microfluidic chambers akin to traditional flow chamber systems used for biofilm analysis into a fully integrated, easy to use microfluidic device.
The BioFlux system includes an instrument with software control and replaceable, sterile multi-well BioPlates™ that contain the entire fluid path. All reagents, including media, inoculant and test compounds, are pre-loaded in the wells and delivered automatically for long-term unattended operation.
Fluxion’s pneumatic fluid control design eliminates the need for cumbersome fluid-filled tubing and pumps. Precise flow and shear rates are maintained by the system’s advanced electronic pressure control system, and temperature control of the fluidics is included.
Each BioPlate is constructed with a cover-slip glass bottom to ensure optimal microscopic image quality. Each 24-well plate can run up to 8 experiments, with as many as 4 experiments running at one time.
According to Cristian Ionescu-Zanetti, Ph.D., Founder and Chief Technology Officer, “originating from needs expressed within the biofilm research community, the BioFlux system has breakthrough capabilities. It provides excellent modeling of the physiological conditions in which biofilms form in a high throughput, easy-to-use, fully integrated package that is ideal for research and drug discovery. Based on data from our early access customers, we believe the system will provide dramatic improvements in experimental throughput, performance, and reproducibility.”
